Becton, Dickinson and Company (NYSE:BDX) Price Target Cut to $261.00 by Analysts at Barclays

Becton, Dickinson and Company (NYSE:BDX) had its target price cut by Barclays from $279.00 to $261.00 in a report released on Monday,Benzinga reports. The brokerage currently has an “overweight” rating on the medical instruments supplier’s stock. Barclays‘s target price indicates a potential upside of 27.84% from the stock’s previous close.

Several other research analysts have also commented on the stock. Piper Sandler upped their price objective on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a report on Tuesday, January 28th. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 2nd. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and an average price target of $275.71.

Becton, Dickinson and Company Trading Down 1.5 %

Shares of NYSE BDX traded down $3.17 during mid-day trading on Monday, hitting $204.17. The stock had a trading volume of 1,433,820 shares, compared to its average volume of 2,082,408. The business has a 50 day moving average price of $230.06 and a two-hundred day moving average price of $231.33. Becton, Dickinson and Company has a 1 year low of $199.37 and a 1 year high of $251.99. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.63 and a current ratio of 1.13. The firm has a market cap of $58.62 billion, a P/E ratio of 33.97, a price-to-earnings-growth ratio of 1.63 and a beta of 0.35.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. On average, equities analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company announced that its Board of Directors has approved a stock repurchase program on Tuesday, January 28th that authorizes the company to repurchase 10,000,000 outstanding shares. This repurchase authorization authorizes the medical instruments supplier to reacquire shares of its stock through open market purchases. Stock repurchase programs are often an indication that the company’s leadership believes its shares are undervalued.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Shana Carol Neal sold 788 shares of the stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $235.00, for a total transaction of $185,180.00. Following the completion of the transaction, the executive vice president now owns 16,201 shares in the company, valued at $3,807,235. This trade represents a 4.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Michael David Garrison sold 597 shares of the business’s stock in a transaction dated Friday, January 17th. The stock was sold at an average price of $236.51, for a total transaction of $141,196.47. Following the completion of the sale, the executive vice president now owns 5,544 shares in the company, valued at approximately $1,311,211.44. This trade represents a 9.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 4,984 shares of company stock valued at $1,147,865 in the last 90 days. Insiders own 0.36% of the company’s stock.

Institutional Trading of Becton, Dickinson and Company

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Bank of Jackson Hole Trust bought a new position in Becton, Dickinson and Company during the fourth quarter valued at $25,000. Sierra Ocean LLC bought a new position in Becton, Dickinson and Company during the 4th quarter valued at about $29,000. REAP Financial Group LLC raised its position in Becton, Dickinson and Company by 75.3% in the 4th quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier’s stock worth $29,000 after purchasing an additional 55 shares during the period. Picton Mahoney Asset Management lifted its stake in Becton, Dickinson and Company by 61.4% in the fourth quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier’s stock worth $32,000 after purchasing an additional 54 shares during the last quarter. Finally, Nexus Investment Management ULC purchased a new position in shares of Becton, Dickinson and Company during the first quarter valued at approximately $34,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.